JP2019504868A5 - - Google Patents

Download PDF

Info

Publication number
JP2019504868A5
JP2019504868A5 JP2018543090A JP2018543090A JP2019504868A5 JP 2019504868 A5 JP2019504868 A5 JP 2019504868A5 JP 2018543090 A JP2018543090 A JP 2018543090A JP 2018543090 A JP2018543090 A JP 2018543090A JP 2019504868 A5 JP2019504868 A5 JP 2019504868A5
Authority
JP
Japan
Prior art keywords
virus
vector according
viral vector
sequence
grna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018543090A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019504868A (ja
JP7176737B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/017652 external-priority patent/WO2017142835A1/en
Publication of JP2019504868A publication Critical patent/JP2019504868A/ja
Publication of JP2019504868A5 publication Critical patent/JP2019504868A5/ja
Application granted granted Critical
Publication of JP7176737B2 publication Critical patent/JP7176737B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018543090A 2016-02-15 2017-02-13 レトロウイルス核酸配列の切除 Active JP7176737B2 (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201662295390P 2016-02-15 2016-02-15
US62/295,390 2016-02-15
US201662298722P 2016-02-23 2016-02-23
US62/298,722 2016-02-23
US201662337994P 2016-05-18 2016-05-18
US62/337,994 2016-05-18
US201662345520P 2016-06-03 2016-06-03
US62/345,520 2016-06-03
US201662363625P 2016-07-18 2016-07-18
US62/363,625 2016-07-18
US201662410496P 2016-10-20 2016-10-20
US62/410,496 2016-10-20
PCT/US2017/017652 WO2017142835A1 (en) 2016-02-15 2017-02-13 Excision of retroviral nucleic acid sequences

Publications (3)

Publication Number Publication Date
JP2019504868A JP2019504868A (ja) 2019-02-21
JP2019504868A5 true JP2019504868A5 (OSRAM) 2020-03-26
JP7176737B2 JP7176737B2 (ja) 2022-11-22

Family

ID=59626223

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018543090A Active JP7176737B2 (ja) 2016-02-15 2017-02-13 レトロウイルス核酸配列の切除

Country Status (9)

Country Link
US (2) US12122997B2 (OSRAM)
EP (1) EP3417062B1 (OSRAM)
JP (1) JP7176737B2 (OSRAM)
CN (1) CN109415728A (OSRAM)
AU (1) AU2017219605B2 (OSRAM)
CA (1) CA3014631A1 (OSRAM)
MX (2) MX2018009904A (OSRAM)
WO (1) WO2017142835A1 (OSRAM)
ZA (2) ZA201806060B (OSRAM)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013066438A2 (en) 2011-07-22 2013-05-10 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
CA2922428A1 (en) 2013-08-29 2015-03-05 Temple University Of The Commonwealth System Of Higher Education Methods and compositions for rna-guided treatment of hiv infection
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US20150166984A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting alpha-antitrypsin point mutations
WO2016022363A2 (en) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
EP3919622A1 (en) 2015-06-01 2021-12-08 Temple University - Of The Commonwealth System of Higher Education Methods and compositions for rna-guided treatment of hiv infection
SG10202104041PA (en) 2015-10-23 2021-06-29 Harvard College Nucleobase editors and uses thereof
CN109415728A (zh) 2016-02-15 2019-03-01 天普大学-联邦高等教育系统 逆转录病毒核酸序列的切除
KR20250103795A (ko) 2016-08-03 2025-07-07 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 아데노신 핵염기 편집제 및 그의 용도
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
SG11201903089RA (en) 2016-10-14 2019-05-30 Harvard College Aav delivery of nucleobase editors
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
EP3592381A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Cancer vaccine
WO2018165629A1 (en) 2017-03-10 2018-09-13 President And Fellows Of Harvard College Cytosine to guanine base editor
WO2018176009A1 (en) 2017-03-23 2018-09-27 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
WO2018209320A1 (en) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
CN111801345A (zh) 2017-07-28 2020-10-20 哈佛大学的校长及成员们 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
EP3676376B1 (en) 2017-08-30 2025-01-15 President and Fellows of Harvard College High efficiency base editors comprising gam
US11795443B2 (en) 2017-10-16 2023-10-24 The Broad Institute, Inc. Uses of adenosine base editors
WO2019118949A1 (en) 2017-12-15 2019-06-20 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
US12157760B2 (en) 2018-05-23 2024-12-03 The Broad Institute, Inc. Base editors and uses thereof
EP3820495A4 (en) 2018-07-09 2022-07-20 The Broad Institute Inc. RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
EP3942043A2 (en) 2019-03-19 2022-01-26 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
CN114258398A (zh) 2019-06-13 2022-03-29 总医院公司 工程化的人内源性病毒样颗粒及使用其递送至细胞的方法
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
EP4114937A4 (en) 2020-03-04 2024-09-04 Flagship Pioneering Innovations VI, LLC METHODS AND COMPOSITIONS FOR MODULATING A GENOME
CN113528514B (zh) * 2020-04-22 2023-05-05 中国科学院分子植物科学卓越创新中心 基于CRISPR-Cas12a干预阻断病毒逆转录转座的技术
BR112022022603A2 (pt) 2020-05-08 2023-01-17 Broad Inst Inc Métodos e composições para edição simultânea de ambas as fitas de sequência alvo de nucleotídeos de fita dupla
CN116670154A (zh) 2020-07-24 2023-08-29 总医院公司 增强的病毒样颗粒及使用其递送至细胞的方法
WO2022071974A1 (en) * 2020-10-02 2022-04-07 Temple University - Of The Commonwealth System Of Higher Education Rna guided eradication of herpes simplex type i and other related human herpesviruses
WO2022232442A2 (en) * 2021-04-28 2022-11-03 Salk Institute For Biological Studies Multiplex crispr/cas9-mediated target gene activation system
EP4347035A4 (en) * 2021-06-01 2025-09-03 Univ Massachusetts CAS9 NICKING-MEDIATED GENE EDITING
WO2023010061A1 (en) * 2021-07-27 2023-02-02 University Of Miami Nanoparticles and uses thereof for treatment of human immunodeficiency virus
KR20260037664A (ko) 2021-09-08 2026-03-18 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 게놈을 조절하기 위한 방법 및 조성물
WO2026039311A1 (en) 2024-08-10 2026-02-19 Vectorgen Lentiviral vector for treating human immunodeficiency virus infection

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
EP0745134A1 (en) 1994-02-22 1996-12-04 Danafarber Cancer Institute Nucleic acid delivery system, method of synthesis and uses thereof
WO2011043830A2 (en) 2009-10-09 2011-04-14 New York University Methods, agents and peptides for inducing an innate immune response in hiv vaccination
WO2014093701A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
IL239317B (en) * 2012-12-12 2022-07-01 Broad Inst Inc Providing, engineering and optimizing systems, methods and compositions for sequence manipulation and therapeutic applications
CA2922428A1 (en) * 2013-08-29 2015-03-05 Temple University Of The Commonwealth System Of Higher Education Methods and compositions for rna-guided treatment of hiv infection
CN104726449A (zh) 2015-03-23 2015-06-24 国家纳米科学中心 一种用于预防和/或治疗HIV的CRISPR-Cas9系统及其制备方法和用途
CN109415728A (zh) 2016-02-15 2019-03-01 天普大学-联邦高等教育系统 逆转录病毒核酸序列的切除

Similar Documents

Publication Publication Date Title
Pal et al. ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A* 01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency
Merten et al. Large-scale manufacture and characterization of a lentiviral vector produced for clinical ex vivo gene therapy application
KR102423444B1 (ko) 레트로바이러스 벡터
Hofmann et al. Species-specific, postentry barriers to primate immunodeficiency virus infection
Doria-Rose et al. Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89. 6P mucosal challenge
RU2018130640A (ru) Способы и композиции для направляемого рнк лечения вич-инфекции
Aguchi et al. Sequence Note: Identification of a New HIV-2 Subtype Based on Phylogenetic Analysis of Full-Length Genomic Sequence
Casimiro et al. Vaccine-induced immunity in baboons by using DNA and replication-incompetent adenovirus type 5 vectors expressing a human immunodeficiency virus type 1 gag gene
JP2018516572A5 (OSRAM)
Evans et al. Immunization of macaques with single-cycle simian immunodeficiency virus (SIV) stimulates diverse virus-specific immune responses and reduces viral loads after challenge with SIVmac239
Takeda et al. Protective efficacy of an AIDS vaccine, a single DNA priming followed by a single booster with a recombinant replication-defective Sendai virus vector, in a macaque AIDS model
CA2387182A1 (en) Lentiviral vectors for the preparation of immunotherapeutical compositions
JP2019527055A5 (OSRAM)
JP2018524335A5 (OSRAM)
DK33190A (da) Hiv-3 retrovirus og anvendelse heraf
RU2009130342A (ru) Применение адаптированных рекомбиназ для лечения ретровирусных инфекций
Hammonds et al. Induction of neutralizing antibodies against human immunodeficiency virus type 1 primary isolates by Gag-Env pseudovirion immunization
JP2003514565A5 (OSRAM)
Mansfield et al. Vaccine protection by live, attenuated simian immunodeficiency virus in the absence of high-titer antibody responses and high-frequency cellular immune responses measurable in the periphery
Patterson et al. Potent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hr-simian immunodeficiency virus (SIV) env/rev, gag, and/or nef vaccines and boosted with SIV gp120
Portis Perspectives on the role of endogenous human retroviruses in autoimmune diseases
Verrier et al. A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates
Otten et al. Induction of broad and potent anti-human immunodeficiency virus immune responses in rhesus macaques by priming with a DNA vaccine and boosting with protein-adsorbed polylactide coglycolide microparticles
CN104039968A (zh) 非b亚型gag蛋白在慢病毒包装中的应用
Lim et al. Specific insertions of zinc finger domains into Gag-Pol yield engineered retroviral vectors with selective integration properties